139 related articles for article (PubMed ID: 31616499)
1. Metastatic MEN1 Syndrome Treated with Lutetium-177 - A Case Report.
Gezer E; Çetinarslan B; Cantürk Z; Tarkun İ; Sözen M; Selek A
Eur Endocrinol; 2019 Aug; 15(2):92-94. PubMed ID: 31616499
[TBL] [Abstract][Full Text] [Related]
2. Metastatic Grade 3 Neuroendocrine Tumor in Multiple Endocrine Neoplasia Type 1 Expressing Somatostatin Receptors.
Graf A; Welch J; Bansal R; Mandl A; Parekh VI; Cochran C; Levy E; Nilubol N; Patel D; Sadowski S; Jha S; Agarwal SK; Millo C; Blau JE; Simonds WF; Weinstein LS; Del Rivero J
J Endocr Soc; 2022 Oct; 6(10):bvac122. PubMed ID: 36111275
[TBL] [Abstract][Full Text] [Related]
3. Peptide Receptor Radionuclide Therapy with
Naik C; Basu S
World J Nucl Med; 2017; 16(2):126-132. PubMed ID: 28553179
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of
Zhang J; Song Q; Cai L; Xie Y; Chen Y
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1533-1543. PubMed ID: 32281025
[TBL] [Abstract][Full Text] [Related]
5. Metastatic Neuroendocrine Tumor with Extensive Bone Marrow Involvement at Diagnosis: Evaluation of Response and Hematological Toxicity Profile of PRRT with (177)Lu-DOTATATE.
Basu S; Ranade R; Thapa P
World J Nucl Med; 2016; 15(1):38-43. PubMed ID: 26912977
[TBL] [Abstract][Full Text] [Related]
6. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
[TBL] [Abstract][Full Text] [Related]
7. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of hitherto unknown brain meningioma detected on
Parghane RV; Talole S; Basu S
World J Nucl Med; 2019; 18(2):160-170. PubMed ID: 31040748
[TBL] [Abstract][Full Text] [Related]
9. Additional hepatic
Braat AJAT; Kwekkeboom DJ; Kam BLR; Teunissen JJM; de Herder WW; Dreijerink KMA; van Rooij R; Krijger GC; de Jong HWAM; van den Bosch MAAJ; Lam MGEH
BMC Gastroenterol; 2018 Jun; 18(1):84. PubMed ID: 29902988
[TBL] [Abstract][Full Text] [Related]
10. Definitive Treatment of Brain Metastases From a Neuroendocrine Tumor With Peptide Receptor Radionuclide Therapy With 177Lutetium DOTATATE: A Case Report.
Zhang V; Taparra K; Fisher G; Aparici C; Soltys SG
Cureus; 2023 Sep; 15(9):e45327. PubMed ID: 37849592
[TBL] [Abstract][Full Text] [Related]
11. Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC.
Severi S; Sansovini M; Ianniello A; Bodei L; Nicolini S; Ibrahim T; Di Iorio V; D'Errico V; Caroli P; Monti M; Paganelli G
Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1955-63. PubMed ID: 26112388
[TBL] [Abstract][Full Text] [Related]
12. Outcome analysis in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy with Lu-177-DOTATATE.
Prétot D; Engel-Bicik I; Kenkel D; Kaufmann PA; Treyer V; Siebenhüner AR
J Gastrointest Oncol; 2023 Jun; 14(3):1204-1217. PubMed ID: 37435198
[TBL] [Abstract][Full Text] [Related]
13.
Thapa P; Parghane R; Basu S
World J Nucl Med; 2017; 16(3):223-228. PubMed ID: 28670182
[TBL] [Abstract][Full Text] [Related]
14. Incidental Detection of Parathyroid Adenoma on Somatostatin Receptor PET/CT and Incremental Role of
Arora S; Damle NA; Passah A; Yadav MP; Ballal S; Aggarwal V; Gupta Y; Kumar P; Tripathi M; Bal C
Nucl Med Mol Imaging; 2018 Jun; 52(3):238-242. PubMed ID: 29942404
[TBL] [Abstract][Full Text] [Related]
15. The Safety and Efficacy of the Repeated PRRT with [
Zemczak A; Gut P; Pawlak D; Kołodziej M; Królicki L; Kos-Kudła B; Ruchała M; Kamiński G; Kunikowska J
Int J Endocrinol; 2021; 2021():6615511. PubMed ID: 33552155
[TBL] [Abstract][Full Text] [Related]
16. Polish experience in Peptide receptor radionuclide therapy.
Kunikowska J; Królicki L; Sowa-Staszczak A; Hubalewska-Dydejczyk A; Pawlak D; Mikolajczak R; Handkiewicz-Junak D; Szaluś N; Kamiński G; Cwikla J; Jakuciński M; Lukiewicz A; Kowalska A; Gut P
Recent Results Cancer Res; 2013; 194():467-78. PubMed ID: 22918776
[TBL] [Abstract][Full Text] [Related]
17. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with
Bergsma H; van Lom K; Raaijmakers MHGP; Konijnenberg M; Kam BLBLR; Teunissen JJM; de Herder WW; Krenning EP; Kwekkeboom DJ
J Nucl Med; 2018 Mar; 59(3):452-458. PubMed ID: 28775205
[TBL] [Abstract][Full Text] [Related]
18. Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours.
Lim LE; Chan DL; Thomas D; Du Y; Tincknell G; Kuchel A; Davis A; Bailey DL; Pavlakis N; Cehic G; Macdonald W; Wyld D; Segelov E
Oncotarget; 2020 Jul; 11(27):2636-2646. PubMed ID: 32676165
[TBL] [Abstract][Full Text] [Related]
19. Salvage peptide receptor radionuclide therapy with [
van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116
[TBL] [Abstract][Full Text] [Related]
20. Neuroendocrine Tumor Therapy with Lutetium-177: A Literature Review.
Maqsood MH; Tameez Ud Din A; Khan AH
Cureus; 2019 Jan; 11(1):e3986. PubMed ID: 30972265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
